Columbia, Maryland – Dr. Ginette Serrero, CEO of A&G Pharmaceutical Inc., DBA Precision Antibody™, will present two posters at the American Association of Cancer Research’s (AACR) Annual Meeting in Orlando, Florida, April 14-19, 2023.
The AACR Annual Meeting is a premier event for cancer researchers and professionals, bringing together the best minds in cancer research. Dr. Serrero’s presentations at the event will showcase the latest advancements of the innovative work of A&G Pharmaceutical/Precision Antibody™.
Serrero’s first presentation, “Development of competing and non-competing fully human internalizing anti-Her2 monoclonal antibodies,” will take place on April 16. The poster will detail the development of fully human internalizing anti-Her2 monoclonal antibodies using recombinant Her2 protein to immunize fully human mice. Serrero will showcase the selection of several high-affinity internalizing antibodies which compete or not with trastuzumab. This research highlights the effectiveness of fully human mice when used for developing monoclonal antibodies against cancer targets.
The second poster, “On-going phase 1A clinical trial for AG01, a first-in-class anti-progranulin (GP88) monoclonal antibody in patients with advanced malignancies,” will be presented on April 18. AG01 is an antibody against progranulin, a target which is elevated in drug resistant cancers and is a first-in-class. In addition to the therapeutic antibody, two companion diagnostics have been developed and clinically validated by A&G Pharmaceutical. This study aims to determine the maximum tolerated dose, safety, of AG01 before initiating the dose expansion portion of the trial.
Precision Antibody™, headquartered in Columbia, Maryland, is a biotechnology company specializing in monoclonal antibody development for research and therapy. Precision Antibody™ has worked with Serrero’s laboratory in developing the fully human anti-Her-2 monoclonal antibodies. The company’s cutting-edge technology and expertise have earned it a worldwide reputation as a leader in the field of monoclonal antibody development in cancer research.
For more information on A&G Pharmaceutical Inc., DBA Precision Antibody™, and its innovative cancer treatments, please visit their website at https://precisionantibody.com/.
Led by innovative minds in immunology and the antibody development field, Precision Antibody has been an industry leader for over 20 years. We not only implement a cutting-edge technique in antigen design, antibody development, production, and other analyses, but we are also constantly working on ways to improve and advance technology to match the ever-changing world of science. If you are interested in learning more about Precision Antibody’s Custom Antibody development.
Precision Antibody™ is the forefront of the global Custom Antibody industry & it is led by the innovative minds in immunology and antibody development field.
